Company Overview and News

Abercrombie & Fitch (ANF) Down 8.1% Since Earnings Report: Can It Rebound?

2017-04-04 zacks
A month has gone by since the last earnings report for Abercrombie & Fitch Company (ANF - Free Report) . Shares have lost about 8.1% in that time frame, underperforming the market.
Upvote Downvote

Vestiaire Collective secures €58 million funding to support further international growth

2017-01-24 prnewswire
- Vitruvian Partners leads the funding round and makes first investment in France - Existing major shareholders Eurazeo and Idinvest Partners reinforce their support - The round will be used to consolidate Vestiaire Collective's leading position in Europe, fuel its growth in the US, and allow for expansion into new markets including Asia Pacific through 2017 - Investment in a unique new logistics facility in France to meet increasing demand in Europe - 120 jobs to be created globally within the next 18 months
Upvote Downvote

Apparel Stocks' Q3 Earnings Slated for Nov 18: FL, BKE, ANF

2016-11-17 zacks
The Q3 earnings season has been grabbing eyeballs not only because it is turning out to be an encouraging one after five straight quarters of earnings declines but it has also coincided with the much-talked about Presidential election wherein Donald Trump triumphed over Hillary Clinton. We are almost at the tail end of the reporting cycle, with the Retail/Wholesale sector in the limelight. Per our Earnings Preview report as of Nov 11, out of the 455 S&P 500 companies that have come up with their quarterly numbers, approximately 72.
Upvote Downvote

Falling Earnings Estimates Signal Weakness Ahead for Abercrombie & Fitch (ANF)

2016-09-14 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
Upvote Downvote

Have You Offloaded Abercrombie & Fitch from Your Portfolio?

2016-09-12 zacks
Are you still holding shares of Abercrombie & Fitch Co. (ANF - Analyst Report) and awaiting a miracle to take the stock higher in the near term? If yes, then odds are you might lose more money as chances are very slim that the stock which lost its value by nearly 25% since Aug 30, 2016, will take a U-turn in the near term.
Upvote Downvote

Fossil to Launch 100 Wearables for Eight Brands in 2016

2016-03-16 zacks
Global consumer fashion accessories maker Fossil Group Inc. (FOSL - Analyst Report) is now geared up to move ahead with wearables and plans to launch more than 100 wearable products including activity trackers and smart watches in 40 countries in 2016. The company announced that eight brands including Chaps, Diesel, Emporio Armani, Fossil, kate spade new york, Michael Kors, Misfit and Skagen will each launch a product in the wearables space in 2016.
Upvote Downvote

Kohl's (KSS) Re-Launches Sonoma Goods For Life Brand

2016-03-15 zacks
Kohl’s Corporation (KSS - Analyst Report) has announced the re-launch of its private brand Sonoma Goods For Life, as part of its focus on delivering ‘amazing product’.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...